UK Prime Minister Keir Starmer announced that the UK will ban social media platforms from providing services to users under the age of 16.

The ban may cover platforms including Snapchat, TikTok, YouTube, Instagram, Facebook and X, with the first batch of regulations potentially taking effect as early as next spring.

The UK plans to follow legislation passed by Australia at the end of last year, while introducing additional restrictions on features deemed harmful to children.
~

AASTOCKS Financial News
Website: www.aastocks.com

Kazakhstan signed an AI project agreement with startup Firebird, with participation from NVIDIA Corporation (NVDA.US), potentially bringing investment of up to USD10 billion.

The agreement includes a strategic cooperation pact to develop AI infrastructure, as well as a large-scale plan to build a project named Data Center Valley in northeastern Kazakhstan.

According to a statement from the Kazakh government, the first phase of Data Center Valley is expected to involve an investment of USD5 billion, including USD1 billion from state-owned Kazakhtelecom.

A 125-megawatt power plant under the project is scheduled to commence commercial operations next year. The launch timing of the second phase and the additional USD5 billion investment will be determined at a later stage.
~

AASTOCKS Financial News
Website: www.aastocks.com

HONG KONG, June 15, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally developed next-generation HER3 antibody-drug conjugate (ADC), AK138D1, as either monotherapy or in combination with ivonescimab for the treatment of advanced breast cancer.

HER3 is broadly expressed across various solid tumors, including breast, ovarian, colon, gastric, lung, skin, and pancreatic cancers, affecting millions of patients globally. While traditional HER3-targeted ADCs have demonstrated therapeutic potential in combination settings, their clinical utility has historically been constrained by dose-limiting toxicities.

AK138D1 is a next-generation, differentiated HER3-targeting ADC developed in-house by Akeso. Leveraging a unique, innovative design, AK138D1 is engineered to reduce uptake in normal tissues, thereby minimizing off-target toxicities and widening the therapeutic window. Furthermore, its design prevents the clustering of ADC molecules on the tumor surface, enhancing deep tissue penetration and uniform distribution to overcome the "binding site barrier". Early-stage clinical studies conducted in China and Australia have demonstrated that AK138D1 exhibits robust anti-tumor activity in solid tumors and breast cancer, coupled with an excellent safety profile, notably characterized by low hematologic toxicity and the absence of interstitial lung disease (ILD). This compelling balance of efficacy and safety overcomes common limitations of conventional ADCs, establishing a foundation for AK138D1 to be explored in diverse combination therapeutic regimens.

The AK138D1-202 study focuses on the two major breast cancer subtypes with the greatest unmet need: hormone receptor-positive, HER2-negative (HR+/HER2-) disease, which accounts for approximately 65% of all breast cancers, and triple-negative breast cancer (TNBC), which represents 10-20% of cases. The trial enrolls patients across multiple treatment lines from treatment-naïve to heavily pretreated, and includes diverse PD-L1 expression levels. Breast cancer remains the most common cancer among women worldwide, with an estimated 2.3 million new cases diagnosed annually. Substantial unmet needs persist in both first-line and later-line settings for HR+/HER2- breast cancer and TNBC.

Early data from AK138D1 studies have already shown meaningful efficacy and a strong safety profile in breast cancer. Concurrently, a Phase III study of ivonescimab-based combination therapy in first-line TNBC is ongoing. The combination of AK138D1 and ivonescimab is poised to emerge as a highly differentiated "IO2.0 + ADC2.0" therapeutic strategy for advanced breast cancer.

As IO+ADC combinations become a cornerstone of global oncology research, Akeso is strategically and efficiently building a comprehensive global portfolio of these next-generation therapies, leveraging its proprietary leadership in bispecific and multispecific antibody platforms.

On the IO front, Akeso stands as the only company globally with two approved bispecific antibodies for oncology, spearheading the advancement of IO2.0 therapies. Regarding its ADC pipeline, Akeso's development of AK146D1 (a Trop2/Nectin4 bispecific ADC) and AK138D1, among other innovations, aims to resolve the toxicity-related limitations of current ADCs and propel the field into the "ADC2.0" era.

About AK138D1

Injectable AK138D1 is a HER3-targeted antibody-drug conjugate (ADC), with a fully humanized anti-HER3 IgG1 antibody, patritumab. It is conjugated to the topoisomerase I inhibitor DXd through a cleavable linker, MC-AAA (maleimide-alanine-alanine-alanine). After binding to HER3 on tumor cells, the ADC is internalized into the tumor cells, where the linker is cleaved, releasing the membrane-permeable DXd. This leads to DNA damage and subsequent cell apoptosis. Early study results have shown that AK138D1 possesses potent biological activity and a favorable safety profile. A phase II clinical trial is currently ongoing to investigate AK138D1 combined with cadonilimab and ivonescimab in patients with solid tumors. This regimen is a critical part of Akeso's IO2.0 + ADC 2.0 combination approach.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.

Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, 27 candidates have advanced into clinical trials—including 15 bispecific or multispecific antibodies and bispecific ADCs—and 8 innovative drugs have reached commercial stage.

Through efficient and groundbreaking R&D, Akeso integrates premier global resources to develop transformative medicines, deliver high-quality, affordable therapeutic antibodies to patients worldwide, and generate sustained commercial and societal value as it strives to become a global leader in biopharmaceutical innovation.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

美國馬里蘭州羅克維爾市和中國蘇州2026年6月15日 /美通社/ -- 致力於在腫瘤等領域開發創新藥物的領先的生物醫藥企業——亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）宣佈，公司核心產品的17項臨床進展已在2026年歐洲血液學協會（EHA）年會上精彩亮相，其中包括8項壁報展示。展示數據涉及公司兩大重磅產品——中國首個上市的第三代BCR-ABL抑制劑奧雷巴替尼（商品名：耐立克^®；研發代號：HQP1351）和中國首個上市的國產原創Bcl-2選擇性抑制劑利沙托克拉（商品名：利生妥^®；研發代號：APG-2575），全面展現了公司在血液腫瘤領域的深厚佈局和全球創新實力。

在本屆EHA年會上，奧雷巴替尼在慢性髓細胞白血病（CML）和費城染色體陽性急性淋巴細胞白血病（Ph+ ALL）雙治療領域同步更新關鍵循證數據：在CML領域，奧雷巴替尼針對無T315I突變的一線TKI耐藥和/或不耐受CML慢性期（CML-CP）患者具有持久且深度的治療效果，呈現強勁的二線治療潛力；針對至少接受過2種TKI治療且治療失敗的CML-CP患者，奧雷巴替尼可以作為一種標準治療；同時該產品針對多線TKI耐藥、合併高危基因突變的CML患者的臨床數據積極。在Ph+ ALL領域，奧雷巴替尼持續展現穩健療效，其一線全球註冊Ⅲ期（POLARIS-1）數據進一步驗證了其優異的深度緩解率與安全可控性；而在兒童復發/難治性Ph+ ALL等細分人群中，與利沙托克拉的無化療聯合方案收穫亮眼臨床數據。

利沙托克拉針對慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）的註冊Ⅱ期數據更新，通過基線特徵與預後相關性分層分析，為後續細化不同人群用藥策略、優化個體化給藥方案提供了重要參考。利沙托克拉在髓系腫瘤的真實世界數據也為其臨床價值提供了強有力的佐證。

亞盛醫藥首席醫學官翟一帆博士表示：「本屆EHA年會上，奧雷巴替尼、利沙托克拉的多項臨床進展獲得展示，進一步證實了這兩款重磅產品在全球血液腫瘤領域的治療價值。奧雷巴替尼有望重塑CML的治療路徑，也為Ph+ ALL患者治療提供全新可能。利沙托克拉在CLL/SLL的註冊II期的數據更新為不同人群的個體化用藥提供了重要參考，在髓系腫瘤的真實世界數據使我們對其在這類患者的應用充滿信心。特別是兩個產品的聯用數據呈現的強勁潛力讓我們倍感興奮。未來，我們將繼續加速推進兩個重磅產品的全球臨床開發進程，同時積極探索更多創新聯合治療方案，為全球患者提供真正具有變革意義的治療選擇。」

在此次EHA年會上展示的精選壁報核心要點如下（更多公司在研品種相關研究數據請查詢EHA官網）：

UPDATED EFFICACY AND SAFETY OF OLVEREMBATINIB (HQP1351) AS SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)

奧雷巴替尼（HQP1351）作為慢性髓細胞白血病慢性期（CP-CML）二線治療的最新療效與安全性

• 摘要編號：EHA-3388 (PS1733)
• 第一作者：黎緯明教授，華中科技大學同濟醫學院附屬協和醫院血液科
• 關鍵信息：這是一項單臂、多中心、開放標籤的II期研究，評估了奧雷巴替尼用於無T315I突變的CP-CML患者的二線治療效果。在42例可評估患者中，完全細胞遺傳學反應（CCyR）率達76.2%，主要分子學反應（MMR）率達47.6%，且反應率隨治療週期遞增，安全性良好，無治療相關死亡。該研究證明，奧雷巴替尼在無T315I突變的一線TKI耐藥和/或不耐受CP-CML患者中具有持久且深度的治療效果，為這類患者提供了重要的二線治療選擇。

EFFICACY OF OLVEREMBATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) WITH PRIOR RESISTANCE TO PONATINIB OR ASCIMINIB AND ASXL1 MUTATIONS

奧雷巴替尼治療既往對泊那替尼和/或阿思尼布耐藥且攜帶ASXL1基因突變的慢性髓細胞白血病慢性期（CP-CML）患者的療效

• 摘要編號：EHA-3991 (PS1727)
• 第一作者：Elias Jabbour, MD，美國德克薩斯大學MD安德森癌症中心白血病科
• 關鍵信息：這是一項Ib期研究，對22例既往接受泊那替尼和/或阿思尼布耐藥的CP-CML患者進行基因分析，評估奧雷巴替尼在不同突變背景下的抗白血病活性。40.9%（9/22）的患者攜帶ASXL1突變。經奧雷巴替尼治療後，44.4%（4/9）的ASXL1突變患者獲得臨床反應，其中22.2%（2/9）達到MMR（其中1例達到MR4.5）。該研究首次證明，奧雷巴替尼對泊那替尼和/或阿思尼布耐藥且攜帶ASXL1突變的CP-CML患者有效，為多重TKI耐藥患者提供了新的治療選擇。

THE EFFICACY AND SAFETY OF SWITCHING TO OLVEREMBATINIB OR CONTINUING ORIGINAL TKI THERAPY IN CML-CP PATIENTS TREATED WITH AT LEAST TWO PRIOR TKIS: A PROSPECTIVE, MULTICENTER, CONTROLLED TRIAL

經至少兩種酪氨酸激酶抑制劑治療的慢性髓細胞白血病慢性期患者轉換用奧雷巴替尼或繼續原TKI治療的療效與安全性：一項前瞻性多中心對照研究

• 摘要編號：EHA-4595 (PS1728)
• 第一作者：文冰冰，深圳市第二人民醫院
• 關鍵信息：這是一項前瞻性、多中心對照試驗，納入105例既往接受≥2種TKI治療≥18個月但未達MMR的CML-CP患者，按1:2分配至奧雷巴替尼組（40mg隔日口服）或繼續原TKI治療組。結果顯示，6個月時奧雷巴替尼組MMR率顯著高於對照組（54.3% vs 10.0%，P<0.001）；12個月時累積MMR率分別為57.14%和21.43%（P<0.0001）。最常見3-4級血液學不良事件為血小板減少（42.86%）和貧血（17.14%），非血液學事件罕見。78.57%的患者在換用奧雷巴替尼後，既往TKI相關AE得到改善。結論支持奧雷巴替尼作為≥2種TKI治療失敗CML-CP患者的潛在標準治療。

UPDATED RESULTS OF POLARIS-1 (PART 1), A GLOBAL REGISTRATIONAL PHASE 3 STUDY: OLVEREMBATINIB COMBINED WITH LOW-INTENSITY CHEMOTHERAPY IN NEWLY DIAGNOSED PH+ ALL

POLARIS-1研究（第一部分）最新結果：奧雷巴替尼聯合低強度化療治療新診斷費城染色體陽性急性淋巴細胞白血病（Ph+ ALL）的全球註冊III期臨床研究

• 摘要編號：EHA-3437 (PS1479)
• 第一作者：陳蘇寧教授，蘇州大學附屬第一醫院
• 這是一項全球多中心註冊性III期研究（POLARIS-1第一部分），評估奧雷巴替尼聯合低強度化療用於新診斷Ph+ ALL的療效與安全性。共入組55例患者，誘導治療結束時CR/CRi率94.4%，微小殘留病（MRD）陰性CR率63.0%； MRD陰性率隨治療週期推進持續升高，至第9治療週期末達93.1%；安全性可控，30mg與40mg劑量組療效與安全性無顯著差異，且對IKZF1^plus等不良預後基因型患者同樣高效。該研究證明，奧雷巴替尼聯合低強度化療可為新診斷Ph+ ALL患者帶來快速、深度且持久的MRD轉陰，安全性良好，為Ph+ ALL一線治療提供了重要依據。

SAFETY AND PRELIMINARY EFFICACY OF OLVEREMBATINIB (HQP1351) COMBINED WITH LISAFTOCLAX (APG-2575) IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY (R/R PH+ ALL): RESULTS OF A PHASE 1B STUDY

一項1B期臨床研究結果：奧雷巴替尼（HQP1351）聯合利沙托克拉（APG-2575）治療復發/難治性（R/R）費城染色體陽性急性淋巴細胞白血病（Ph+ ALL）兒童患者的安全性與初步療效

• 摘要編號：EHA-4691 (PS1473)
• 第一作者：章婧嫽，中國醫學科學院血液病醫院（中國醫學科學院血液學研究所）
• 關鍵信息：這是一項開放標籤、劑量遞增Ib期研究評估奧雷巴替尼聯合利沙托克拉治療既往≥1種TKI耐藥或不耐受的兒童R/R Ph+ ALL患者。共入組17例患者，中位年齡13歲，40%攜帶ABL1突變（含T315I）。9例可評估療效的患者中，聯合治療後ORR高達88.9%，MRD陰性率達66.7%（8/12，第2週期第28天），93.3%的患兒（14/15，第2週期第28天）獲得MMR及更深分子緩解；兩藥均可透過血腦屏障，對ABL1突變患者均有效，安全性可控且無治療相關死亡。該研究證明，該無化療口服雙靶向方案可帶來快速、深度緩解，為兒童R/R Ph+ ALL提供全新治療選擇。

REAL-WORLD EFFICACY AND SAFETY OF LISAFTOCLAX IN MYELOID NEOPLASMS: A MULTICENTER STUDY

一項多中心研究：利沙托克拉用於髓系腫瘤的真實世界療效與安全性

• 摘要編號：EHA-5454 (PF562)
• 第一作者：曹晨，山東大學齊魯醫院
• 關鍵信息：這是一項國內多中心真實世界研究（回顧性），旨在評估新型Bcl-2抑制劑利沙托克拉在髓系腫瘤中的療效與安全性。共納入30例患者（中位年齡為63歲），其中急性髓系白血病（AML）25例（83%）、骨髓增生異常綜合征（MDS）3例（10%）、慢性粒單核細胞白血病（CMML）2例（7%）。AML患者CR/CRi高達72%，其中ELN低危組療效最佳（87%），首次達到CR/CRi的患者中MRD陰性率達61%。NPM1突變患者CR/CRi率為100%，IDH2 突變患者為83%。3例MDS患者中，2例達到CRi。安全性方面，≥3級治療期間不良事件（TEAEs）主要為血細胞減少（血小板減少27%，貧血23%，中性粒細胞減少20%），整體可控。該研究表明，利沙托克拉在真實世界中治療髓系腫瘤（特別是AML）具有優異的療效和可控的安全性。

CORRELATION OF BASELINE CHARACTERISTICS WITH PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) TREATED WITH LISAFTOCLAX (APG-2575) IN A PIVOTAL PHASE 2 STUDY

一項關鍵II期臨床研究中利沙托克拉（APG-2575）治療的慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者基線特徵與預後的相關性

• 摘要編號：EHA-3984 (PS1713)
• 第一作者：周可樹教授，河南省腫瘤醫院
• 關鍵信息：這是一項基於關鍵II期研究NCT05147467的相關性分析，旨在探索利沙托克拉治療R/R CLL/SLL患者時基線特徵與預後的關係。研究納入77例既往BTKi治療失敗的患者，接受利沙托克拉600mg每日一次治療。在72例可評估患者中，中位PFS為23.9個月，IRC評估ORR為62.5%。進一步分析顯示，TP53突變/del(17p)、複雜核型、基數較大的腫瘤病灶及SF3B1、KIT、BLM、SETD2突變與較差預後相關，其中複雜核型和腫瘤大小是PFS縮短的獨立風險因素。該研究提示，利沙托克拉在BTKi治療失敗後的R/R CLL/SLL患者中具有明確療效，並可通過基線風險特徵進一步識別預後較差人群，為後續風險分層和聯合治療策略提供依據。

關於亞盛醫藥

亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）是一家綜合性的全球生物醫藥企業，致力於研發、生產和商業化創新藥，以解決腫瘤領域全球患者尚未滿足的臨床需求。公司已建立豐富的創新藥產品管線，包括抑制Bcl-2和 MDM2-p53 等細胞凋亡通路關鍵蛋白的抑制劑、新一代針對癌症治療中出現的激酶突變體的抑制劑以及蛋白降解劑。

公司核心品種耐立克^®是中國首個獲批上市的第三代BCR-ABL抑制劑，已獲批用於治療伴有T315I突變的慢性髓細胞白血病慢性期（CML-CP）和加速期（CML-AP）患者，以及對一代和二代TKI耐藥和/或不耐受的CML-CP成年患者。該藥物所有獲批適應症均已被納入中國國家醫保藥品目錄（NRDL）。目前，亞盛醫藥正在開展耐立克^®三項全球註冊III期臨床研究，分別為：獲美國FDA和歐洲EMA許可的評估耐立克^®治療新診斷費城染色體陽性急性淋巴細胞白血病（Ph+ ALL）患者POLARIS-1研究；獲美國FDA和歐洲EMA許可的評估耐立克^®治療經治CML-CP成年患者的POLARIS-2研究；評估耐立克^®治療SDH-缺陷型GIST患者的POLARIS-3研究。

公司另一重磅品種利生妥^®是一款用於治療多種血液系統惡性腫瘤的新型Bcl-2抑制劑。利生妥^®已獲中國國家藥品監督管理局（NMPA）批准，用於治療既往至少接受過一種包括布魯頓酪氨酸激酶（BTK）抑制劑在內的系統治療的成人慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者。目前，亞盛醫藥正在開展利生妥^®四項全球註冊III期臨床研究，分別為：獲美國FDA和歐洲EMA許可的評估利生妥^®聯合BTK抑制劑治療既往接受BTK抑制劑治療超過12個月且應答不佳的CLL/SLL患者的GLORA研究；評估利生妥^®一線治療初治CLL/SLL患者的GLORA-2研究；評估利生妥^®一線治療新診斷老年或不耐受的AML患者的GLORA-3研究；以及獲美國FDA和歐洲EMA許可的評估利生妥^®一線治療新診斷中高危MDS患者的GLORA-4研究。

憑借強大的研發能力，亞盛醫藥已在全球範圍內進行知識產權佈局，並與武田、阿斯利康、默沙東、輝瑞、信達等眾多領先的生物製藥公司達成全球合作，同時與丹娜法伯癌症研究院、梅奧醫學中心、美國國家癌症研究所和密西根大學等學術機構建立研發合作關係。如需瞭解更多信息，請訪問 https://ascentage.com/

前瞻性聲明

本新聞稿包含根據美國《1995年私人證券訴訟改革法案》，以及經修訂的《1933年證券法》第27A條和《1934年證券交易法》第21E條所界定的前瞻性陳述。除歷史事實陳述外，本新聞稿中的所有內容均可能構成前瞻性陳述，包括亞盛醫藥對未來事件、經營成果或財務狀況所發表的意見、預期、信念、計劃、目標、假設或預測。

這些前瞻性陳述受到諸多風險和不確定性的影響，具體內容已在亞盛醫藥向美國證券交易委員會（SEC）提交的文件中詳細說明，包括2026年4月29日提交的20-F表格中截止2025年12月31日的年度報告中的「風險因素」和「關於前瞻性聲明的警示聲明」章節，2019年10月16日提交的首次發行上市招股書中的「前瞻性聲明」、「風險因素」章節，以及我們不時向SEC或HKEX提交的其他文件。這些因素可能導致實際業績、運營水平、經營成果或成就與前瞻性陳述中明示或暗示的信息存在重大差異。本前瞻性聲明中的陳述不構成公司管理層的利潤預測。

因此，該等前瞻性陳述不應被視為對未來事件的預測。本新聞稿中的前瞻性陳述僅基於亞盛醫藥當前對未來發展及其潛在影響的預期和判斷，且僅代表截至陳述發表之日的觀點。無論出現新信息、未來事件或其他情況，亞盛醫藥均無義務更新或修訂任何前瞻性陳述。

上海2026年6月15日 /美通社/ -- 近日，全球領先的人工智能（AI）+機器人藥物與新材料研發平台晶泰科技（2228.HK）宣佈，其與中石化（上海）石油化工研究院有限公司、北京精微高博儀器有限公司聯合打造的「智能化物理/化學吸附分析自主實驗工作站」正式投入運營，以智能化、自動化的材料表徵驅動化工研發，為「AI for Science」（科學智能，AI4Science）的材料發現引擎打造了關鍵的物理載體與具身智能底座。它首次在產業級場景中，將材料表徵的高通量數據收集與實驗自主決策，完整納入了「AI + 機器人 + Multi-Agent」的智能體系，邁出了通往物理 AI（Physical AI）的關鍵一步，為材料研發構建「可感知、可操作、可進化」的智能自主研發體系奠定基礎。

本次成果集中體現了三大核心技術標籤：全流程無人化自主實驗、原生高質量數據閉環、軟硬一體的模塊化智能基座。這一合作成果將材料表徵這一高頻剛需環節，從經驗驅動的手工作坊式操作，升級為數據驅動、AI決策的工業級智能系統，實現表徵通量、數據精度與實驗安全的量級躍升。

強強聯合，打造AI+材料表徵行業標桿

在石油化工、新能源、環保等萬億級產業中，對材料的精確表徵是研發流程中高頻、剛需、且極大依賴人力與個人經驗試錯的關鍵環節。多孔材料（如分子篩、活性炭、金屬有機框架材料等）作為石油化工中應用最廣、用量最大的催化劑和吸附劑載體，其比表面積、孔徑分佈及表面酸性等特性，直接決定了催化裂化、加氫處理、氣體分離等核心工藝的效率與選擇性，堪稱石化產業的「芯片」。傳統表徵模式高度依賴人工操作，不僅效率與通量低下，更因個人主觀經驗與操作差異導致數據一致性差，使得海量的實驗數據無法有效反哺 AI 模型，成為制約新材料智能研發的最大數據瓶頸。

為破解這一難題，晶泰科技與中石化（上海）石油化工研究院和精微高博通力合作，構建了從產業問題定義、高端儀器研發到AI自主實驗全流程閉環的協同創新生態，將傳統上依賴直覺和經驗的分析過程，轉變為可量化、可重複的科學方法，直擊產業核心痛點。

本次合作中，中石化（上海）石油化工研究院憑借石油化工領域豐富的研發積澱與深刻的產業場景理解，精準提出高通量、高精準、高安全的工業級核心需求，並提供真實嚴苛的驗證場景；精微高博作為國產物理/化學吸附儀器的領先企業，為工作站打造「精準感官」的高精度分析儀器硬件底座，確保AI自主實驗數據的精準性與可靠性；晶泰科技作為AI for Science領域的標桿企業，為合作注入「AI大腦」與機器人自主操控能力，依托其「AI+機器人+Multi-Agent」的閉環自主運行的智能系統，將獨立運行的儀器升級為能自主規劃流程、解析數據、做出決策的「AI 材料表徵科學家」，三方深度創新協同，為行業樹立材料表徵的智能化新標桿。

AI驅動自主實驗，重塑材料表徵核心範式

本工作站以AI原生為內核，將靈活、可擴展的機器人實驗工站兼容併入智能算法統一實驗標準，形成了一套「軟硬一體」的智能化系統，實現從樣品處理到數據分析的全流程無人化閉環，為 AI for Science賦能材料科學構築「高質量數據底座」：

• 高通量自主實驗：工作站支持多通道物理/化學吸附模塊的智能拓展，可在AI統一調度下自主分配任務，實現 7×24小時無人化不間斷運行，日均樣品處理量獲得數量級躍升，將研究人員從重複勞動中徹底解放。

• 原生高質量數據閉環：機器人操作統一實驗標準，從根本上消除了人為誤差。系統兼容併入核心智能算法，保障了數據的超高一致性與可重複性，為AI模型訓練提供高質量數據支撐，讓每一組數據都可追溯、可復用。

• 本質安全與智能分析：無人化運行顯著降低了傳統實驗中液氮接觸等操作風險，提升了實驗室本質安全。系統還能自動完成數據分析、結果歸一化與趨勢建模，為材料研發的數字化、智能化轉型奠定了基礎。

這套系統基於晶泰科技成熟可定制的AI自主實驗平台開發而來，該平台擁有 30餘種功能模塊，可靈活組合，已獲全球超300家頂尖企業與科研機構認可。

構築數據基石，推動產業向物理 AI 邁進

「智能化物理/化學吸附分析自主實驗工作站」通過全流程數字化與自主運行，首次實現了實驗數據的完整捕獲與結構化沉澱，將原本分散、易逝的個人經驗轉化為可積累、可復用的數據資產。其意義不僅在於單點效率的提升，更為構建能夠理解並作用於物理世界的AI模型提供了高質量「數據燃料」，讓材料理性設計真正有機會從海量實驗數據中發現構效關係，形成「實驗-數據-模型-預測」的閉環進化能力。

中石化（上海）石油化工研究院有限公司業務相關負責人表示：「該智能工作站以AI與自主實驗技術，引入催化劑研發的核心環節，不僅在效率與數據精準度上實現躍升，更為我們探索高性能、低能耗催化劑提供了全新的研究範式，助力'雙碳'目標下產業綠色低碳轉型，是化工研發智能化轉型的標桿實踐。」

晶泰科技自動化創新業務負責人表示：「這是AI for Science在石油化工領域的重要突破。我們正在構建的，是一套能夠讓AI持續產生、消化高質量數據，並驅動自我迭代的研發基礎設施。以此為起點，這一模式將從吸附表徵拓展至更廣泛的材料研發場景，推動材料研發從'經驗驅動'轉向'數據驅動、智能驅動'，賦能更多行業的源頭創新。」

北京精微高博儀器相關負責人表示：「本次合作是國產儀器與AI自主實驗技術融合的典範，我們將持續提升產品智能化水平，為全球用戶提供更完整的材料表徵數智化解決方案。」

未來，晶泰科技將繼續深化AI for Science平台型技術，驅動材料研發從經驗探索走向更深層次的機理認知與理性設計，在工業場景中持續打磨以垂類AI模型、大規模機器人實驗室、Multi-Agent為核心的研發飛輪，加速我國材料研發領域全面智能化升級，為服務科技強國戰略與產業高質量發展注入持久動能。

關於中石化（上海）石油化工研究院有限公司

中石化（上海）石油化工研究院是中國石化集團公司直屬的綜合性石油化工科研機構，致力於石油化工、合成樹脂、合成纖維、催化劑等領域的技術研發和產業化應用，為中國石化的技術進步和產業升級提供核心支撐。

關於精微高博

精微高博成立於 2004 年，總部和研發中心設於北京，生產基地位於天津，在美國、德國設有子公司，是一家深耕全球市場的科學儀器製造企業。公司產品涵蓋吸附類儀器、熱分析儀器、X 射線衍射儀及反應裝置等關鍵領域。作為全球材料分析儀器領域的創新推動者，精微始終秉持「為新材料的研究和製造提供高質量、高易用性、高性價比的先進測量儀器」的使命，持續探索材料表徵前沿技術，加速技術迭代，為全球客戶提供多元化產品及服務解決方案。

關於晶泰科技

晶泰科技（「XtalPi Holdings Limited」，股份簡稱：晶泰控股，XTALPI，股票代碼：2228.HK）由三位麻省理工學院的物理學家於 2015 年創立，是一個基於量子物理、以人工智能賦能和機器人驅動的創新型研發平台。公司採用基於量子物理的第一性原理計算、人工智能、高性能雲計算以及可擴展及標準化的機器人自動化相結合的方式，為製藥及材料科學（包括農業技術、能源及新型化學品以及化妝品）等產業的全球和國內公司提供藥物及材料科學研發解決方案及服務。

• AmiGo, an on-demand autonomous mobility service between Baidu's Apollo Go and Swiss Post's PostBus, has received a special permit from Switzerland's Federal Roads Office (FEDRO) for Level 4 autonomous operations in Eastern Switzerland, confirming the service meets Switzerland's rigorous safety and quality requirements.
• Open-road autonomous driving trials began on June 1, 2026, across an approximately 80 km² service area in the cantons of St. Gallen, Appenzell Ausserrhoden, and Appenzell Innerrhoden.
• Provided all safety and regulatory requirements are met, regular fully driverless operations are expected to launch in early 2027, with Apollo Go powering what is set to be the largest planned automated public transport operation of its kind in Europe.

BEIJING, June 12, 2026 /PRNewswire/ -- Baidu, Inc. (NASDAQ: BIDU and HKEX: 9888) today announced that AmiGo, the on-demand autonomous mobility service developed through a partnership between Apollo Go and PostBus, has received a special operating permit from the Federal Roads Office (FEDRO) for Level 4 autonomous operations in Eastern Switzerland. AmiGo vehicles have been conducting open-road testing since June 1, 2026, marking a major development in Apollo Go's European expansion and validating the global readiness of its autonomous driving technology.

The FEDRO special permit confirms that AmiGo's vehicles and autonomous driving system meet Switzerland's clearly defined safety and quality requirements, underscoring the maturity and reliability of Apollo Go's globally proven technology. Autonomous driving trials with a safety operator on board now cover an approximately 80 km² service area across the cantons of St. Gallen, Appenzell Ausserrhoden, and Appenzell Innerrhoden.

"Automated driving evolves through real-world operating experience. That is exactly what AmiGo represents. With the largest trial of this kind, Switzerland is reaching a new dimension: multiple vehicles, a real service area, and a concrete public transport offering. The FEDRO permit provides the framework — with clear requirements, defined responsibilities, and the objective of learning from operations for the next steps," said Jürg Röthlisberger, Director of FEDRO.

"Receiving FEDRO 's special permit is an important milestone for AmiGo and a strong validation of our technology. Under Switzerland's rigorous safety framework, AmiGo represents an important step toward integrating autonomous mobility into the country's public transport system. We look forward to working closely with PostBus to deliver a safe, reliable, and sustainable service for communities in Eastern Switzerland," said Nan Yang, Vice President of Baidu and General Manager of Overseas Business Unit, Intelligent Driving Group.

"With AmiGo, we are making automated mobility in public transport tangible," said Stefan Regli, CEO of PostBus and member of the Executive Board of Swiss Post. "The special permit from FEDRO shows that we can implement operations step by step and under clearly defined safety requirements. Our focus is on building a safe and reliable service that meaningfully complements existing public transport."

AmiGo brings together Apollo Go's RT6 vehicles and autonomous driving expertise with PostBus's deep knowledge of Swiss public transport operations. The service complements the existing public transport network, particularly in areas where conventional services reach their limits, and is fully electric and bookable via the AmiGo app.

The next phase will involve a closed-group user trial, followed by initial rides without safety operators once all safety evidence is fully provided. The longer-term goal is to launch regular operations from 2027, with rides bookable via the AmiGo app. The service, which is expected to be the largest planned automated public transport operation of its kind in Europe, will be deployed using Apollo Go RT6 vehicles. Each RT6 vehicle is fully electric, carries up to three passengers, and is equipped with over 30 sensors enabling comprehensive environmental perception and real-time onboard data processing. The steering wheel is designed to be removed once the service transitions to fully autonomous operations.

Apollo Go is the world's leading autonomous ride-hailing platform, with a proven track record of large-scale operations. In the first quarter of 2026, Apollo Go delivered 3.2 million fully driverless rides, with weekly rides peaking at over 350,000 in March, representing 120% year-over-year growth. As of April 2026, cumulative rides provided to the public exceeded 22 million. Apollo Go's global footprint now spans 27 cities, and its fleets have accumulated over 330 million autonomous kilometers as of May, including over 220 million fully driverless kilometers.

About Baidu:

Founded in 2000, Baidu's mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong internet foundation, trading on the NASDAQ under "BIDU" and HKEX under "9888." One Baidu ADS represents eight Class A ordinary shares.

ISTANBUL, June 12, 2026 /PRNewswire/ -- At the recently concluded KOMATEK 2026 exhibition, Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion"; 1157.HK) made a powerful impression under the theme "Innovation for Value". Showcasing over 40 advanced products alongside its localized sales and service framework, the company garnered extensive acclaim from global customers. During the event, Zoomlion secured over 1 billion RMB (approx. $138 million USD) in new and intentional orders, highlighting its market leading position and the rapid momentum of its international development.

Localization and customization stood out as core features of Zoomlion's exhibition lineup. To address the rigorous operating conditions and regulatory frameworks of Turkey and its surrounding markets, the company presented several tailored equipment solutions. A key highlight was the ZLK7600V803 knuckle boom crane, a specialized model manufactured locally at Zoomlion's factory in Germany. The crane features a superstructure manufactured by Zoomlion's German subsidiary, WILBERT, integrated with a premium, locally sourced European Scania chassis. Fully certified under CE standards and meeting all European road transport regulations, this model seamlessly blends Zoomlion's long-standing structural optimization and control technologies. Offering exceptional lifting performance, high quality, and cost-efficiency, this benchmark machine serves as a compelling example of Zoomlion's "global village mindset" in driving international industrial collaboration and deeper market integration.

This deep integration of cross-border technological innovation and overseas localized manufacturing is a direct result of Zoomlion's "1+N" global manufacturing strategy. Under this blueprint, "1" represents the Zoomlion Smart City in China—the central hub for advanced research and primary exporter of core technologies and innovative products. The "N" signifies a growing network of overseas localized manufacturing facilities and service platforms positioned across key strategic markets worldwide. Currently, Zoomlion has established 13 overseas R&D and manufacturing bases, more than 30 primary regional aviation hubs, and over 400 sales and service outlets, with its products and services covering over 170 countries and regions. Through this expansive network, Zoomlion is constructing a highly collaborative global industrial framework.

As one of Zoomlion's core strategic markets, Turkey exemplifies this deeply localized approach. Since establishing its Istanbul subsidiary in 2018, Zoomlion has built a robust network of 12 comprehensive service branches and 3 central warehouses across the country. The recent openings of the Denizli branch (3,500 sq. m.) and the Bursa branch (1,200 sq. m.) have further solidified Zoomlion's capability to serve as a critical regional hub for sales, technical maintenance, and spare parts. This extensive direct infrastructure effectively establishes an integrated "end-to-end" platform combining administration, warehousing, logistics, and customer support for the region.

Concurrently, Zoomlion is extending its localized manufacturing capabilities deeper into Europe. In Tatabánya, Hungary, Zoomlion's modern AWP intelligent factory officially commenced Phase I operations in 2026. Strategically positioned at a major logistics corridor connecting Eastern and Western Europe, this 250-mu (approx. 16.5-hectare) facility specializes in high-quality boom and scissor lifts. This setup significantly enhances regional supply chain efficiency and product availability while fostering strong, mutually beneficial synergies with local industrial ecosystems.

Meanwhile, Zoomlion is driving a landmark transformation at its primary European manufacturing hub in Germany. Following the acquisition of tower crane manufacturer WILBERT in 2018, the site has steadily evolved into a multi-category industrial base. In 2025, Zoomlion broke ground on Phase II of the factory, an investment exceeding EUR 50 million covering over 60,000 square meters. Upon reaching full capacity, the expanded facility will produce over 1,000 units of tower cranes, mobile cranes, and concrete machinery annually, serving as a comprehensive overseas production hub and a vital bridgehead for Zoomlion's long-term growth in Europe.

The rollout of the "1+N" strategy delivers distinct operational advantages to both Zoomlion and its global customers. First, it significantly improves delivery efficiency and product adaptability, as manufacturing and assembling equipment closer to end markets allows Zoomlion to respond more swiftly to regional standards and customer preferences. Second, closer coordination among these global bases enhances supply chain resilience. Through mutual resource integration between domestic and overseas facilities, Zoomlion has optimized regional logistics networks and ensured a stable, consistent, and reliable product supply for international construction machinery markets. Finally, supported by an end-to-end service network and direct direct-to-customer operations, Zoomlion provides comprehensive lifecycle maintenance support, building deep commercial trust and establishing a solid foundation for mutual success with global clients.

From product innovation to intelligent manufacturing, and from local production to direct service support, Zoomlion continues to root itself in local markets with a "global village mindset". Driven by continuous technological R&D and localized operations, the company refines its products to match global needs while strengthening connections worldwide. Moving forward, Zoomlion remains committed to open cooperation, leveraging its industry-leading R&D capabilities, comprehensive manufacturing systems, and professional service networks to work alongside global customers and partners toward a sustainable future.

——  11% above WLTP to 646 km and 12m55s charge secure double victory at NAF El Prix Summer 2026

AMSTERDAM, June 12, 2026 /PRNewswire/ -- The XPENG X9 recorded the largest positive deviation from WLTP range and the fastest charging time among all vehicles tested in the summer edition of El Prix 2026, the world's largest independent electric vehicle test organised by the Norwegian Automobile Federation (NAF) and Motor magazine.

The seven-seater achieved the highest result among all 24 vehicles tested, delivering a leading 11.4% positive deviation versus its official WLTP range. In real-world conditions, it covered a total of 646 km and continued operating for more than 11 hours after the start of the test. NAF noted that the XPENG X9 "clearly stood out" in this year's range evaluation.

The X9 also delivered the fastest charging performance, going from 10% to 80% in 12 minutes and 55 seconds. At the El Prix Winter 2026 held in February, the model again topped the field at -10°C with a 12-minute charge. While Europe's current 400 kW charging infrastructure has yet to fully unlock the X9's maximum capability, the vehicle continues to achieve top-tier charging times across different environments.

The result makes the XPENG X9 the standout performer of El Prix and further demonstrates the real world benefits of XPENG's latest generation EV technology.

"Recording the largest WLTP range deviation and the fastest charging time is strong validation of the technology behind the XPENG X9," said Alex Tang, General Manager of International Business at XPENG. "Customers should not have to choose between long range and fast charging. The X9 delivers both, helping drivers spend more time on the road and less time waiting at a charger."

Held twice a year, El Prix is widely regarded as the world's largest independent comparison of electric vehicle range and charging performance. The results are closely followed by consumers, media and manufacturers across Europe. 

The XPENG X9 is one of new XPENG models launching in Europe during 2026, with Norway serving as the first market. Combining long range capability, ultra‑fast charging and premium comfort for up to seven passengers, it plays a key role in XPENG's continued growth ambitions across one of the world's most advanced EV regions.

About XPENG

Founded in 2014, XPENG is a leading Chinese-born AI-driven mobility company that designs, develops, manufactures, and markets Smart EVs, catering to a growing base of tech-savvy consumers. With the rapid advancement of AI, XPENG aspires to become a global leader in AI mobility, with a mission to drive the Smart EV revolution through cutting-edge technology, shaping the future of mobility. To enhance the customer experience, XPENG develops its full-stack advanced driver-assistance system (ADAS) technology and intelligent in-car operating system in-house, along with core vehicle systems such as the powertrain and electrical/electronic architecture (EEA). Headquartered in Guangzhou, China, XPENG also operates key offices in Beijing, Shanghai, Silicon Valley, and Amsterdam. Its Smart EVs are primarily manufactured at its facilities in Zhaoqing and Guangzhou, Guangdong province.

XPENG is listed at the New York Stock Exchange (NYSE: XPEV) and Hong Kong Exchange (HKEX: 9868).

For more information, please visit https://www.xpeng.com/.

Media Contacts
XPENG PR Department
Email: [email protected]

NVIDIA Corporation (NVDA.US) informed Chinese clients that its Vera central processing unit (CPU) for AI data centers could be launched as early as August, with customers able to start placing orders, Reuters, citing sources, reported.

CEO Jensen Huang said in October last year that the company’s market share in China had effectively fallen to zero, under the influence of US export controls on advanced chips.

Some Chinese clients have shown interest in Vera, NVIDIA’s first CPU designed for agentic AI, sources divulged. Vera is now in full production and operates 1.8x faster than comparable processors from competitors.

When Huang unveiled Vera in March, the company said leading cloud computing enterprises, including BABA-W (09988.HK) and ByteDance, were working with NVIDIA to deploy Vera, though it is unclear whether the actual ordering process has begun.
~

AASTOCKS Financial News
Website: www.aastocks.com

HONG KONG, June 12, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111), the company's internally-developed anti-IL-17 monoclonal antibody, for the treatment of adult patients with moderate-to-severe plaque psoriasis.

The approval was supported by one pivotal Phase III clinical study (AK111-301) and three supportive studies. Study results demonstrate gumokimab's rapid and robust efficacy, durable complete skin clearance, and favorable safety and dosing profile. Treatment demonstrated rapid onset of action, with clinically meaningful improvement observed as early as Week 2.

• Rapid and robust efficacy at Week 12: Gumokimab achieved a PASI 75 response rate of 94.6% and a complete skin clearance rate (PASI 100) of 47.7%, substantially higher than the 28.6% PASI 100 response rate observed with other agents in the same class.
• Durable complete clearance through Week 52: The PASI 75 response rate approached 100%, while the PASI 100 response rate reached 68.9%, markedly higher than the 39.2% reported for other drugs in the same class.
• Favorable safety profile: The incidences of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and infections/infestations were numerically among the lowest rates of TEAEs, SAEs, and infections/infestations reported in pivotal trials of IL-17-inhibitors.
• Convenient dosing regimen: Gumokimab utilizes a convenient subcutaneous dosing regimen requiring only 17 injections annually (including loading phase), approximately half the annual injection burden of other IL-17 inhibitors that require more frequent maintenance dosing. Reduced injection frequency has the potential to improve long-term adherence and persistence in moderate-to-severe plaque psoriasis.

Professor Xu Jinhua, Principal Investigator of the pivotal Phase III registration study for gumokimab at Huashan Hospital, Fudan University:

"Psoriasis is a chronic, lifelong condition that demands long-term standardized management. Beyond the physical burden of skin lesions, it significantly impairs patients' quality of life, work, social functioning, and mental well-being. Achieving deep and sustained skin clearance with good tolerability remains a major unmet need. Gumokimab, an IgG1 monoclonal antibody that precisely targets IL-17, has demonstrated rapid onset, strong short-term efficacy, durable long-term control, and a favorable safety profile in clinical studies. We are delighted by its approval, which offers patients a more effective, convenient, and reliable new treatment option."

Dr. Xia Yu, Founder, Chairwoman, President and CEO of Akeso:

"I would like to thank all the investigators, study teams, and patients who participated in the clinical development of gumokimab. Their contributions have enabled us to deliver this important new therapy to the approximately 6.7 million psoriasis patients.

To better address patients' diverse needs, Akeso has successfully developed and launched ebdarokimab and gumokimab, two therapies targeting distinct pathogenic pathways that complement each other. The autoimmune disease field remains one of the largest and fastest-growing areas in innovative drug development. With these two approvals, we have built a strong, differentiated portfolio for psoriasis. Manfidokimab is advancing in late-stage development across multiple indications, while our first-in-class IL-4R/ST2 bispecific antibody AK139 and other novel agents continue to progress rapidly. This growing immunology and inflammation platform is enhancing product synergies and strengthening Akeso's global competitiveness."

In addition to moderate-to-severe plaque psoriasis, a supplemental New Drug Application (sNDA) for gumokimab in active ankylosing spondylitis has been accepted for review by the Center for Drug Evaluation (CDE) of the NMPA.

About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization model, the company has evolved into a globally competitive biopharmaceutical focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 27 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs), 8 innovative drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

Forward-Looking Statements
This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.